About: Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources
Creator	Hinrichs, Steven Koepsell, Scott Abdalhamid, Baha Bilder, Christopher Iwen, Peter Mccutchen, Emily
source	MedRxiv; Medline
abstract	Objectives To establish the optimal parameters for group testing of pooled specimens for the detection of SARS-CoV-2. Methods The most efficient pool size was determined to be 5 specimens using a web-based application. From this analysis, 25 experimental pools were created using 50 microliter from one SARS-CoV-2 positive nasopharyngeal specimen mixed with 4 negative patient specimens (50 microliter each) for a total volume of 250 microliter l. Viral RNA was subsequently extracted from each pool and tested using the CDC SARS-CoV-2 RT-PCR assay. Positive pools were consequently split into individual specimens and tested by extraction and PCR. This method was also tested on an unselected group of 60 nasopharyngeal specimens grouped into 12-pools. Results All 25 pools were positive with Cycle threshold (Ct) values within 0 and 5.03 Ct of the original individual specimens. The analysis of 60 specimens determined that two pools were positive followed by identification of two individual specimens among the 60 tested. This testing was accomplished while using 22 extractions/PCR tests, a savings of 38 reactions. Conclusions When the incidence rate of SARS-CoV-2 infection is 10% or less, group testing will result in the saving of reagents and personnel time with an overall increase in testing capability of at least 69%.
has issue date	2020-04-06(xsd:dateTime)
bibo:doi	10.1101/2020.04.03.20050195
bibo:pmid	32511649
has license	medrxiv
sha1sum (hex)	4d91ff2ff4418b7f8958bc5f6a5b1e1c5b157ba5
schema:url	https://doi.org/10.1101/2020.04.03.20050195
resource representing a document's title	Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources
has PubMed identifier	32511649
schema:publication	medRxiv : the preprint server for health sciences
resource representing a document's body	covid:4d91ff2ff4418b7f8958bc5f6a5b1e1c5b157ba5#body_text
is schema:about of	named entity 'The United States' named entity 'assays' named entity 'Wuhan' named entity 'group testing' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'FDA' named entity 'preprint' named entity 'epidemiology' named entity 'real time PCR' named entity 'preprint' named entity 'infectious disease' named entity 'CDC' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'SARS CoV' named entity 'medRxiv' named entity 'preprint' named entity 'doi' named entity 'SARS-CoV-2' named entity 'transfusion' named entity 'Group testing' named entity 'preprint' named entity 'preprint' named entity 'Group testing' named entity 'medRxiv' named entity 'nasopharyngeal' named entity 'preprint' named entity 'epidemic' named entity 'preprint' named entity 'public health' named entity 'preprint' named entity 'spread of disease' named entity 'reverse transcription' named entity 'human immunodeficiency virus' named entity 'China' named entity 'peer-reviewed' named entity 'causative agent' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'laboratory test' named entity 'RNA' named entity 'COVID' named entity 'sensitivity and specificity' named entity 'preprint' named entity 'group testing' named entity 'viral RNA' named entity 'blood products' named entity 'peer-reviewed' named entity 'medRxiv' named entity 'medRxiv' named entity 'COVID-19' named entity 'COVID' named entity 'proof-of-concept' named entity 'pathogen' named entity 'SARS CoV' named entity 'prevalence rate' named entity 'Centers for Disease Control and Prevention' named entity 'peer-reviewed' named entity 'viruses' named entity 'RNA' named entity 'group testing' named entity 'SARS-CoV-2' named entity 'CLINICAL' named entity 'ACUTE' named entity 'positive test' named entity 'Nebraska' named entity 'nasopharyngeal' named entity 'Group testing' named entity 'COVID-19' named entity 'preprint' named entity 'algorithm' named entity 'doi' named entity 'peer-reviewed' named entity 'doi' named entity 'medRxiv' named entity 'SARS CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software